AVHHL (AVITA Medical) Total Liabilities : $68.82 Mil (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is AVITA Medical Total Liabilities?

AVITA Medical's Total Liabilities for the quarter that ended in Sep. 2024 was $68.82 Mil.

AVITA Medical's quarterly Total Liabilities declined from Mar. 2024 ($64.81 Mil) to Jun. 2024 ($63.91 Mil) but then increased from Jun. 2024 ($63.91 Mil) to Sep. 2024 ($68.82 Mil).

AVITA Medical's annual Total Liabilities increased from Jun. 2021 ($9.85 Mil) to Dec. 2022 ($13.52 Mil) and increased from Dec. 2022 ($13.52 Mil) to Dec. 2023 ($62.58 Mil).

AVITA Medical Total Liabilities Historical Data

The historical data trend for AVITA Medical's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVITA Medical Total Liabilities Chart

AVITA Medical Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

4.95

10.06

9.85

13.52

62.58

AVITA Medical Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial															18.04	62.58	64.81	63.91	68.82

AVITA Medical Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

AVITA Medical's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	13.199	+	(41.514	+	3.851
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	4.02	+	0)
	=	62.58

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	111.64	-	49.056
	=	62.58

AVITA Medical's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	17.141	+	(45.626	+	2.983
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	3.074	+	0)
	=	68.82

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	81.051	-	12.227
	=	68.82

AVITA Medical Total Liabilities Related Terms

Thank you for viewing the detailed overview of AVITA Medical's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

AVITA Medical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AVITA Medical Inc (OTCPK:AVHHL) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

RCEL:USA 51KA:Germany 51KB:Germany AVH:Australia

Address

28159 Avenue Stanford, Suite 220, Valencia, Los Angeles, CA, USA, 91355

Website

https://www.avitamedical.com

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.